Effects of Diethylstilboestrol on Insulin-like Growth Factor Levels in Breast Cancer Patients
Author Information
Author(s): Helle S I, Geisler J, Anker G B, Leirvaag B, Holly J M P, Lønning P E
Primary Institution: Haukeland University Hospital
Hypothesis
How does treatment with diethylstilboestrol affect the insulin-like growth factor system in patients with metastatic breast cancer?
Conclusion
The study found significant decreases in several insulin-like growth factors and binding proteins after treatment, indicating a reduced bioavailability of IGFs.
Supporting Evidence
- Significant decreases in IGF-I, IGF-II, and free IGF-I were observed after treatment.
- IGFBP-2 and IGFBP-3 levels also decreased significantly.
- IGFBP-1 and IGFBP-4 levels increased significantly during treatment.
- The findings suggest a reduced bioavailability of IGFs from plasma to tissues.
Takeaway
This study looked at how a medicine called diethylstilboestrol changes certain proteins in the blood of breast cancer patients, showing that it lowers some important growth factors.
Methodology
Fasting blood samples were taken from patients before and during treatment, and various insulin-like growth factors and binding proteins were measured.
Participant Demographics
Patients with metastatic breast cancer
Statistical Information
Confidence Interval
95% confidence intervals of the mean
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website